June 24, 2021

To
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol - Biocon

Subject: - Newspaper Advertisement

Dear Sir / Madam,

Pursuant to Regulation 30 and 47 of SEBI Listing Regulations, please find enclosed the copies of newspaper advertisement published on June 23, 2021 in Financial Express (English Language) and Vijayavani (Kannada Language), in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that 43rd Annual General Meeting of the Company will be held on Friday, July 23, 2021 at 3.30 pm IST through Video Conferencing / Other Audio Visual Means.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
NOTICE - 43rd ANNUAL GENERAL MEETING OF BIOCON LIMITED TO BE HELD THROUGH VIDEO CONFERENCE OR OTHER AUDIO-VISUAL MEANS AND REMOTE E-VOTING FACILITY

Shareholders may note that due to continuing COVID-19 pandemic, the 43rd Annual General Meeting ('AGM') of Biocon Limited ('the Company') will be held on Friday, July 23, 2021 at 3:30 PM through video conferencing ('VC') or other audio-visual means ('OAVM'), to transact the business that will be set forth in the 43rd AGM Notice, in compliance with circular No. 14/2020 dated April 8, 2020, Circular No.17/2020 dated April 13, 2020, Circular No. 20/2020 dated May 5, 2020 and Circular No. 02/2021 dated January 13, 2021 issued by the Ministry of Corporate Affairs ('MCA'), Government of India read with provisions of the Companies Act, 2013 and all other applicable laws.

In compliance with the aforesaid circulars and SEBI circular dated May 12, 2020 and January 15, 2021, the Notice of 43rd AGM along with the Annual Report for the FY 2020-21 will be sent only by electronic mode to those shareholders whose email IDs are registered with the Company/Depositories. Shareholders may note that the Notice of AGM along with the Annual Report will also be available on the website of the Company at www.biocon.com and websites of the stock exchanges i.e. www.bseindia.com and www.nseindia.com.

Shareholders may attend and participate in the AGM through the VC/OAVM facility only. The instructions for joining the AGM will be provided in the Notice of the AGM.

Shareholders, who have not registered their email IDs with the depository participants, are requested to do the following:

• Shareholders holding shares in demat mode are requested to register their email IDs with their depository participants;

• Shareholders holding shares in physical mode are requested to submit their request with their valid e-mail IDs to the Registrar and Share Transfer Agent (‘RTA’) of the Company at einward.ris@kfintech.com or to the Company at co.secretary@biocon.com.

for receiving all communications including annual report, notices, instruction for e-voting and participation in the AGM through VC/OAVM etc., in electronic mode from the Company.

The Company will be providing remote e-voting facility to all its shareholders to cast their votes on all resolutions as set forth in the 43rd AGM Notice. The manner of remote e-voting for shareholders holding shares in demat and physical mode and who have not registered their email IDs, will be provided in the 43rd AGM Notice and the details will be also made available on the website of the Company at www.biocon.com.

For Biocon Limited
Sd/-
Mayank Verma
Company Secretary

Place: Bengaluru
Date : June 22, 2021
COVID-19 is continuing to be a major threat to public health. Biocon, a leading biopharmaceutical company, has been at the forefront of the fight against this pandemic. In a recent statement, CEO of Biocon, V. K. R. Srinivasan, said, "We are committed to delivering innovative medicines to address the global health crisis."

Biocon has been working tirelessly to develop and manufacture vaccines and therapeutics to combat COVID-19. The company has also been supporting the government's vaccination drive by providing essential supplies.

Biocon's contributions in the fight against COVID-19 include the development of a COVID-19 rapid test kit, which has been approved by the Indian Council of Medical Research (ICMR). The kit is designed to provide results in just 30 minutes.

Biocon's work is not limited to India. The company has also been collaborating with international partners to expand its reach and impact. In a recent collaboration, Biocon has partnered with the University of Oxford to develop a COVID-19 vaccine candidate. The vaccine is currently in clinical trials.

In conclusion, Biocon continues to be a leader in the fight against COVID-19. The company's efforts are commendable and its commitment to public health is inspiring. The world is grateful for the contributions made by companies like Biocon in the fight against this pandemic.